Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Merck Sharp & Dohme LLC
- Study ID
- NCT03833167
- Phase
- PHASE3
- Status
- Completed
Conditions
- Carcinoma, Squamous Cell
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pembrolizumab — BIOLOGICAL400 mg IV infusion
- Placebo — DRUGPlacebo-matched IV infusion
Study Details
This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).
Key Dates
- Start date
- Apr 1, 2019
- Status verified
- Feb 2026
- Primary completion
- Jun 28, 2024
- Completion
- Jan 20, 2026
Study Design
- Enrollment
- 450 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: PembrolizumabParticipants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.
- Placebo Comparator: PlaceboParticipants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.
Primary Outcome Measure
Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy [ Time Frame: Up to approximately 62 months ]
Locations (30)
Related coverage on Hipa.ai
- Pembrolizumab Adjuvant Therapy for cSCC Does Not Significantly Improve RFSPembrolizumab · Jul 22, 2025 · ClinicalTrials.gov
Find similar trials in Mobile, AL
By research site
University of South Alabama, Mitchell Cancer Institute· Mobile, ALCity of Hope Medical Center· Duarte, CAUCSD Moores Cancer Center· La Jolla, CAUCLA Hematology/Oncology - Westwood (Building 100)· Los Angeles, CAUniversity of California Davis Comprehensive Cancer Center· Sacramento, CAStanford University Medical Center· Stanford, CA
Related Studies
- Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCCPHASE1 · Recruiting · Melissa Pugliano-Mauro · Pittsburgh, Pennsylvania
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California
- Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCCRecruiting · UNC Lineberger Comprehensive Cancer Center · Rochester, Minnesota
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCPHASE3 · Recruiting · Johnson & Johnson Enterprise Innovation Inc. · Birmingham, Alabama